Research Radartracking 72 published studies · 21 human · 14 clinical trials · 14 cancer pages · updated Jun 2026Open the Research Map →

Neuroblastoma

Auto-discovered from research; not yet curated.

Auto-added · review pending
Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

OncoForge editorial · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

Evidence at a glanceAnimal onlyReported positive
2 published studies that name Neuroblastoma0 human studies (trial, observational, or meta-analysis)786 source documents in the Neuroblastoma corpus
Why this grade?

Animal only — Animal studies only — no human data.

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

Living document — last change June 9, 2026: New cancer type added.

Overview

Neuroblastoma is tracked here from the published studies that mention it. This page shows the research evidence collected so far — it is not a curated clinical overview.

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
10
Meta-analysis
36
Systematic review
40
Randomized trial
0
Clinical trial
6
Observational
4
Case report
167
Review
523
Preclinical
0
Other
0

Evidence on specific compounds

How the published studies grade individual drugs, supplements, and other agents in Neuroblastoma — each rated by how strong the evidence is, not a recommendation.

What recent studies report in Neuroblastoma

These are reviewed studies whose abstracts concern Neuroblastoma. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Neuroblastoma. Most are early lab, animal, or small human studies, and findings often conflict.

2 studies1 animalMechanism (1)

Tracking 2 published studies of Neuroblastoma: 1 in animals, 1 reviews/other.

Reported direction across studies: 2 positive.

No human studies yet — these are preclinical (lab/animal) findings that may not translate to people.

These counts summarize what the studies reported; they are not a measure of whether anything works for Neuroblastoma.

Animal studyReported positivePreclinical onlyTier 2 · animal

A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers

Nature communications · Aug 2025 · xenograft antitumor assays

neuroblastomarhabdomyosarcomacolorectal carcinomamelanomaovarian carcinomabreast carcinoma

This study tested a humanized antibody-drug conjugate called CDX0239-PBD in ALK-expressing cancer models. In cell lines, it was taken up by ALK-positive neuroblastoma cells and killed them in a way that depended on surface ALK expression. In mouse xenograft models, it produced strong antitumor activity and complete responses were maintained in several ALK-expressing cancers.

Key findings
  • ALK RNA, protein, and tumor cell surface expression was elevated in multiple pediatric and adult malignancies with minimal expression in childhood normal tissues.
  • CDX0239-PBD was internalized in ALK-expressing neuroblastoma cell lines with cell surface expression-dependent cytotoxicity.
  • CDX0239-PBD exhibited potent antitumor efficacy including maintained complete responses in ALK-expressing patient and cell line-derived neuroblastoma, fusion-positive rhabdomyosarcoma, and colorectal carcinoma xenograft models.
Limitations: Preclinical study only; no human treatment data are reported in the abstract.; Efficacy was shown in cell lines and xenograft mouse models, which may not predict clinical benefit.; No quantitative effect sizes, dosing details, or toxicity results are provided in the abstract..

The abstract describes a preclinical anticancer antibody-drug conjugate targeting ALK-expressing tumors.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewMechanismReported positiveLimited evidenceTier 4 · clinical

The role of CT10 regulation of kinase-like in cancer

Future oncology (London, England) · Dec 2014 · Review

gastric cancerglioblastoma multiformehepatocellular carcinomabladder cancerlung cancercolon cancerovarian cancerleukemiabreast cancerhead and neck cancerrhabdomyosarcomaneuroblastoma

This is a narrative review summarizing published reports about the adaptor protein CRKL in cancer. The authors report that CRKL is overexpressed in many tumor types and appears to promote aggressive or malignant behaviors, and they suggest CRKL has potential as a diagnostic/prognostic biomarker.

Key findings
  • CRKL is a member of the CRK family and functions as an adaptor protein in intracellular signal transduction.
  • CRKL has been reported overexpressed in a variety of cancers.
  • CRKL appears to play a tumor-promotion role in multiple cancers, including those listed in the abstract.
  • The review summarizes associations between CRKL and malignant tumor behaviors and potential mechanisms of action.
  • The authors state CRKL has potential to be used as a biomarker for diagnosis, treatment and prognosis of certain tumors.
Limitations: This is a review article and does not present new primary experimental data.; Abstract provides no information on search strategy, inclusion criteria, or quality assessment of included studies.; Heterogeneity across many cancer types and study designs likely limits generalizability of conclusions.; The abstract does not report quantitative synthesis or effect sizes..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Browse all studies mentioning Neuroblastoma →

Clinical trials in Neuroblastoma

Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →

Heading to an appointment? Get a printable one-page summary — studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment →